Daily Intelligence Brief
## Uber Assault Litigation Surges Past 3,500 Cases as California Courts Absorb 52 New Filings
The Uber Technologies, Inc., Passenger Sexual Assault Litigation (MDL 3084) has accelerated to roughly 3,462 pending actions (3,410 per previous tracking, plus 52 new filings this week), with Cutter Law PC, MCH Law PLLC, and Schlesinger Law Offices PA driving the California cluster. The filing velocity now rivals the Depo-Provera Products Liability Litigation (MDL 3140), which added 69 complaints this week, and the Hair Relaxer Litigation (MDL 3060), which absorbed 62. Notably, the Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation (MDL 3092) registered 8 new filings before Judge Michael J. Newman in the Northern District of Ohio — a modest but steady pulse in a docket that has remained relatively quiet. The Zantac (Ranitidine) Products Liability Litigation (MDL 2924) also saw unexpected activity with 8 new complaints in the Eastern District of Pennsylvania, suggesting plaintiff firms may be positioning for renewed proceedings after the 2022 MDL dismissal.
## Ozempic Gastroparesis MDL Faces Critical Daubert Deadline as Filing Volume Accelerates
The Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability (Gastroparesis) Litigation (MDL 3094) faces a pivotal May 5, 2026 deadline for defendants' Daubert motions to exclude general-causation experts before Judge Karen S. Marston in the Eastern District of Pennsylvania. The litigation absorbed 36 new filings this week, bringing the estimated docket to roughly 1,847 pending actions (1,811 per JPML's March 1 report, plus ~36 new filings tracked since). Morgan & Morgan PA and McGowan Hood Felder Phillips LLC continue to dominate intake. The Daubert ruling will determine whether plaintiffs can clear the general-causation hurdle for gastroparesis claims — a gatekeeping decision that will shape settlement leverage across the entire GLP-1 portfolio. Defendants Eli Lilly and Novo Nordisk have signaled aggressive expert challenges targeting the biological plausibility of rapid-onset gastric paralysis following GLP-1 initiation.
## Hotel Sex Trafficking Claims Proliferate Despite JPML Denial as Salesforce Enters Crosshairs
Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.
